Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

The major limitation of cord blood transplantation (CBT) for adults remains the delayed hematopoietic recovery and higher incidence of graft failure, which result in a higher risk of early mortality in CBT. We evaluated early overall survival (OS), non‐relapse mortality (NRM), neutrophil engraftment, acute graft‐vs‐host disease, and cause of early death among 9678 adult patients who received single‐unit CBT in Japan between 1998 and 2017. The probability of OS at 100 days was 64.4%, 71.7%, and 78.9% for the periods 1998 to 2007, 2008 to 2012, and 2013 to 2017, respectively (P < .001). The cumulative incidences of NRM at 100 days during the same period were 28.3%, 20.8%, and 14.6%, respectively (P < .001). The cumulative incidences of neutrophil engraftment were also improved during the same period (P < .001). The most common cause of death within 100 days after CBT was bacterial infection in 1998 to 2007 and primary disease in the latter two time periods. Across the three time periods, the proportions of deaths from bacterial and fungal infection, graft failure, hemorrhage, sinusoidal obstructive syndrome, and organ failure decreased in a stepwise fashion. Landmark analysis of OS and NRM after 100 days showed that OS did not change over time in the multivariate analysis. Our registry‐based data demonstrated a significant improvement of early OS after CBT for adults over the past 20 years. The landmark analysis suggested that improvement of early mortality could lead to an improvement of long‐term OS after CBT.

[1]  R. Vij,et al.  Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research , 2019, Haematologica.

[2]  J. Sierra,et al.  Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study , 2019, Leukemia.

[3]  Hisashi Yamamoto Single cord blood transplantation in Japan; expanding the possibilities of CBT , 2019, International Journal of Hematology.

[4]  J. Wagner,et al.  Cord blood research, banking, and transplantation: achievements, challenges, and perspectives , 2019, Bone Marrow Transplantation.

[5]  J. Kurtzberg,et al.  Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014). , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Y. Kanda,et al.  Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades , 2018, Bone Marrow Transplantation.

[7]  M. Pepper,et al.  Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape , 2018, Stem cells translational medicine.

[8]  Peter Bader,et al.  An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia , 2017, Clinical Cancer Research.

[9]  J. Kanda Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation , 2015, International Journal of Hematology.

[10]  Y. Atsuta Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) , 2015, International Journal of Hematology.

[11]  R. Hartzman,et al.  Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  K. Izutsu,et al.  Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[14]  H. Nakasone,et al.  Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  K. Ballen,et al.  Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.

[16]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Kawa,et al.  Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry , 2013, Bone Marrow Transplantation.

[18]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[19]  J. Wingard,et al.  Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  M. Pasquini,et al.  Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[22]  H. Azuma,et al.  The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.

[23]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[24]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  K. Kawa,et al.  Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System , 2007, International journal of hematology.

[26]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[27]  H. Deeg,et al.  Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. , 2003, Blood.

[28]  S. Asano,et al.  Immunological reconstitution after cord blood transplantation for an adult patient , 1999, Bone Marrow Transplantation.

[29]  V. Barbu,et al.  Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. , 1996, The New England journal of medicine.

[30]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[31]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[32]  H. Broxmeyer,et al.  Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Nakahata,et al.  Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hemopoietic progenitors. , 1982, The Journal of clinical investigation.

[34]  T. Montgomery The umbilical cord. , 1960, Clinical obstetrics and gynecology.